Emergency Therapeutics Opportunity Adamis has FDA approved SYMJEPI epinephrine for anaphylaxis and ZIMHI naloxone for opioid overdose. This approved portfolio suits hospital systems, emergency medical services, urgent care centers, and community pharmacies. Opportunities include bundled emergency kits, clinician training programs, and distributor partnerships to expand access.

Post Merger Synergy The 2023 merger with DMK Pharmaceuticals and new leadership creates cross sell opportunities and expanded distribution reach. Leverage DMK networks and the expanded management team to accelerate market expansion and support the Tempol COVID therapy in Phase 2/3 trials.

Capital Readiness The company closed an 8 million public offering in 2023 and holds about 52 million in funding. This capital supports capacity expansion, scale up manufacturing, and potential partnerships or joint ventures to accelerate growth.

Strategic Focus Core focus areas allergy, opioid overdose, respiratory and inflammatory disease align with large and ongoing demand in emergency care and therapy. This positioning supports sales plays with hospital networks, urgent care centers, EMS, and payer programs.

nimble Partner San Diego base with a compact team of 11 to 50 employees offers agility for contract manufacturing, distribution partnerships, or targeted programs with specialty distributors and providers. This size enables rapid pilots and tailored collaborations.